Details:

Alternative Title:
J Int AIDS Soc
Personal Author:
Suraratdecha, Chutima ; Stuart, Robyn M ; Manopaiboon, Chomnad ; Green, Dylan ; Lertpiriyasuwat, Cheewanan ; ... More +
Suraratdecha, Chutima ; Stuart, Robyn M ; Manopaiboon, Chomnad ; Green, Dylan ; Lertpiriyasuwat, Cheewanan ; Wilson, David P ; Pavaputanon, Patcharaporn ; Visavakum, Prin ; Monkongdee, Patama ; Khawcharoenporn, Thana ; Tharee, Phiphatthananon ; Kittinunvorakoon, Chonticha ; Martin, Michael Less -
Description:
Introduction

In 2014, the Government of Thailand recommended pre‐exposure prophylaxis (PrEP) as an additional HIV prevention programme within Thailand's National Guidelines on HIV/AIDS Treatment Prevention. However, to date implementation and uptake of PrEP programmes have been limited, and evidence on the costs and the epidemiological and economic impact is not available.

Methods

We estimated the costs associated with PrEP provision among men having sex with men (MSM) participating in a facility‐based, prospective observational cohort study: the Test, Treat and Prevent HIV Programme in Thailand. We created a suite of scenarios to estimate the cost‐effectiveness of PrEP and sensitivity of the results to the model input parameters, including PrEP programme effectiveness, PrEP uptake among high‐risk and low‐risk MSM, baseline and future antiretroviral therapy (ART) coverage, condom use, unit cost of delivering PrEP, and the discount rate.

Results

Drug costs accounted for 82.5% of the total cost of providing PrEP, followed by lab testing (8.2%) and personnel costs (7.8%). The estimated costs of providing the PrEP package in accordance with the national recommendation ranges from US$223 to US$311 per person per year. Based on our modelling results, we estimate that PrEP would be cost‐effective when provided to either high‐risk or all MSM. However, we found that the programme would be approximately 32% more cost‐effective if offered to high‐risk MSM than it would be if offered to all MSM, with an incremental cost‐effectiveness ratio of US$4,836 per disability‐adjusted life years (DALY) averted and US$7,089 per DALY averted respectively. Cost‐effectiveness acceptability curves demonstrate that 80% of scenarios would be cost‐effective when PrEP is provided solely to higher‐risk MSM.

Conclusion

We provide the first estimates on cost and cost‐effectiveness of PrEP in the Asia‐Pacific region, and offer insights on how to deliver PrEP in combination with ART. While the high drug cost poses a budgeting challenge, incorporating PrEP delivery into an existing ART programme could be a cost‐effective strategy to prevent HIV infections among MSM in Thailand.


Subject:
[+]
Anti-HIV Agents
Cohort Studies
Cost-Benefit Analysis
Delivery Of Health Care
HIV Infections
Homosexuality, Male
Humans
Male
Pre-Exposure Prophylaxis
Prospective Studies
Quality-Adjusted Life Years
Sexual And Gender Minorities
Sexual Behavior

Source:
J Int AIDS Soc. 21(Suppl Suppl 5).
Pubmed ID:
30033559
Pubmed Central ID:
PMC6055129
Document Type:
Journal Article
Place as Subject:
Thailand
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:f8cd8f528765e8a2f20426cc4f37c6d7b3a0388a990c5a474b3cc7b3f4917ac1
File Type:

Supporting Files

• 	JIA2-21-e25129-g001.gif	gif
  	JIA2-21-e25129-g001.jpg	jpeg
  	JIA2-21-e25129-g002.gif	gif
  	JIA2-21-e25129-g002.jpg	jpeg
  	JIA2-21-e25129.nxml	xml

More +